1. Home
  2. EVER vs OMER Comparison

EVER vs OMER Comparison

Compare EVER & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EverQuote Inc.

EVER

EverQuote Inc.

HOLD

Current Price

$25.00

Market Cap

885.7M

Sector

Technology

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$9.81

Market Cap

772.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVER
OMER
Founded
2008
1994
Country
United States
United States
Employees
356
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
885.7M
772.8M
IPO Year
2018
2008

Fundamental Metrics

Financial Performance
Metric
EVER
OMER
Price
$25.00
$9.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
5
Target Price
$27.00
$32.50
AVG Volume (30 Days)
729.3K
1.8M
Earning Date
05-04-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
198.86
98.15
EPS
0.51
0.62
Revenue
$163,349,000.00
$29,868,000.00
Revenue This Year
$14.73
N/A
Revenue Next Year
$11.51
$233.22
P/E Ratio
$48.04
$16.58
Revenue Growth
N/A
N/A
52 Week Low
$13.88
$3.44
52 Week High
$28.73
$17.65

Technical Indicators

Market Signals
Indicator
EVER
OMER
Relative Strength Index (RSI) 54.76 47.35
Support Level $23.67 $9.40
Resistance Level $27.10 $10.77
Average True Range (ATR) 1.43 0.55
MACD -0.29 0.05
Stochastic Oscillator 19.79 44.94

Price Performance

Historical Comparison
EVER
OMER

About EVER EverQuote Inc.

EverQuote Inc operates an online marketplace for insurance shopping, connecting consumers with insurance providers, including carriers and agents. Its marketplace is powered by proprietary data and technology platform that delivers high-intent, pre-validated consumer referrals aligned with insurers underwriting and profitability requirements. The platform provides transparency and campaign management tools, enabling providers to evaluate marketing spend performance and manage return on investment. Consumers can visit insurance provider websites, engage by phone, or submit data to receive quotes. Services are free for consumers, and the company derives revenue principally from consumer inquiries sold as referrals to insurance providers. It derives a majority of revenue from Direct channels.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: